COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study

Prasugrel and ticagrelor are potent P2Y 12 -ADP receptor antagonists which are superior to clopidogrel in acute coronary syndromes. To date no clinical trial directly compared these two drugs. Platelet reactivity correlates with ischemic and bleeding events in patients undergoing percutaneous corona...

Full description

Saved in:
Bibliographic Details
Published in:Platelets (Edinburgh) 2015-01, Vol.26 (6), p.570-572
Main Authors: Laine, Marc, Gaubert, Mélanie, Frère, Corinne, Peyrol, Michael, Thuny, Franck, Yvorra, Serge, Chelini, Virginie, Bultez, Bruno, Luigi, Stephane, Mokrani, Zair, Bessereau, Jacques, Toesca, Richard, Champenois, Anne, Dignat-George, Françoise, Paganelli, Franck, Bonello, Laurent
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - blood
Acute Coronary Syndrome - diagnosis
Acute Coronary Syndrome - drug therapy
Adenosine - administration & dosage
Adenosine - analogs & derivatives
Adenosine - pharmacokinetics
Aged
Electrocardiography
Female
Humans
Male
Middle Aged
Myocardial Infarction - blood
Myocardial Infarction - diagnosis
Myocardial Infarction - drug therapy
Platelet Activation - drug effects
Platelet Aggregation Inhibitors - administration & dosage
Platelet Aggregation Inhibitors - pharmacokinetics
Platelet Function Tests
Platelet reactivity
prasugrel
Prasugrel Hydrochloride - administration & dosage
Prasugrel Hydrochloride - pharmacokinetics
Purinergic P2Y Receptor Antagonists - administration & dosage
Risk Factors
ST-segment elevation myocardial infarction
ticagrelor
Treatment Outcome
VASP-index
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prasugrel and ticagrelor are potent P2Y 12 -ADP receptor antagonists which are superior to clopidogrel in acute coronary syndromes. To date no clinical trial directly compared these two drugs. Platelet reactivity correlates with ischemic and bleeding events in patients undergoing percutaneous coronary intervention. Recent pharmacological studies have observed a delayed onset of action of these two drugs in ST-segment elevation myocardial infarction (STEMI). We provide the first adequately powered pharmacological study comparing PR following ticagrelor and prasugrel loading dose (LD) in STEMI patients when the maximal biological effect is reached. In the present study, ticagrelor was associated with a lower rate of high on-treatment PR compared to prasugrel.
ISSN:0953-7104
1369-1635
DOI:10.3109/09537104.2014.959914